Apricus to stop funding French units; will focus on Vitaros and Femprox
USA-based Apricus Biosciences (Nasdaq: APRI) says that it intends to cease financing its French subsidiaries, Finesco, its French holding company, Scomedica, its French sales company and NexMed Pharma its marketing company.
In line with its previously stated corporate strategy, the company will continue to focus its resources on commercializing its lead product Vitaros (alprostadil 0.3% topical cream), for the treatment of erectile dysfunction and on further developing through clinical trials it lead product candidate, Femprox (alprostadil 0.4% topical cream), for the treatment of female sexual arousal disorder.
Cites negative pricing policies in France for decision
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze